Secondary analysis of clinical trial data suggests that a functional polymorphism ( rs@ , Asn@Asp ) of the - opioid receptor gene ( OPRM@ ) is associated with the risk of relapse to heavy drinking following treatment with the opioid antagonist naltrexone .